Best Bone Cancer Doctors in Hyderabad — CION's Dedicated Bone & Sarcoma Panel

The best doctor depends on whether you have primary bone cancer (osteosarcoma, Ewing sarcoma, chondrosarcoma, giant cell tumour) or metastatic bone disease (cancer that spread to bone from elsewhere). For primary bone sarcomas, look for a medical oncologist current with sarcoma-specific chemotherapy protocols, paired with orthopaedic oncology subspecialty surgery. For metastatic bone disease, the primary cancer's oncologist leads, supported by radiation oncology for pain and bone-modifying agents. At CION, every bone cancer case is reviewed by a multidisciplinary tumour board, with medical oncology led by Dr. T. Raghavender Reddy and limb-sparing surgery coordinated with accredited orthopaedic oncology partners.

This is the single most important distinction. Primary bone cancer means the cancer started in the bone itself — common types are osteosarcoma (most common in adolescents and young adults), Ewing sarcoma (children and young adults), chondrosarcoma (adults), and giant cell tumour of bone (locally aggressive). Metastatic bone disease means the cancer started somewhere else (commonly breast, prostate, lung, kidney, or thyroid) and spread to bone. In adults, metastatic bone disease is far more common than primary bone cancer. The two are treated completely differently. The first job of the tumour board is to confirm which one you have through biopsy and staging — getting this wrong leads to entirely wrong treatment.

Modern orthopaedic oncology can preserve the limb in approximately 90% of bone sarcoma cases through limb-sparing surgery — typically tumour resection followed by reconstruction with a megaprosthesis (custom-made implant), allograft (donor bone), or vascularised fibula graft. Amputation is reserved for tumours with extensive neurovascular involvement, recurrence after limb-sparing surgery, or where pre-operative chemotherapy has not produced adequate response. Long-term outcomes (survival, recurrence) are equivalent between limb-sparing and amputation for appropriately selected cases. CION coordinates limb-sparing surgery with accredited orthopaedic oncology partners across Hyderabad — the surgery itself is highly subspecialised and best done by surgeons who perform it regularly.

Both — but in the right order. A general orthopaedic surgeon may have ordered the X-ray or MRI that found the tumour, and may have performed the initial biopsy. From there, the case must move to oncology. For primary bone sarcomas, medical oncology leads with chemotherapy first (which is typically given before surgery), then surgery is coordinated with an orthopaedic oncologist (subspecialty), followed by post-operative chemotherapy. For metastatic bone disease, the primary cancer's oncologist leads. A general orthopaedic surgeon alone is not the right pathway — they can refer you correctly, but should not be running the cancer treatment plan.

Osteosarcoma is the most common primary bone cancer in adolescents and young adults, typically arising in the long bones (around the knee, around the shoulder). Standard treatment is the MAP regimen — methotrexate (high-dose), doxorubicin, and cisplatin — given in three phases: pre-operative (neoadjuvant) chemotherapy for around 10 weeks, surgery (limb-sparing where feasible), and post-operative (adjuvant) chemotherapy. The total treatment runs about 9–12 months. Five-year survival for localised disease is around 70–75% with this regimen. CION's medical oncology team delivers MAP per current NCCN protocols, with surgery coordinated through accredited orthopaedic oncology partners.

Ewing sarcoma is a primary bone cancer most common in children, adolescents, and young adults, often arising in pelvic bones, long bones of the legs, or chest wall. It is highly responsive to both chemotherapy and radiation — making it one of the few bone cancers where radiation plays a major role. Treatment involves induction chemotherapy (typically VDC/IE — vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide), local control with either surgery or radiation, and then consolidation chemotherapy. Five-year survival for localised disease is around 70–80%. CION's medical and radiation oncology teams deliver Ewing protocols directly; surgical local control is coordinated through accredited orthopaedic oncology partners.

Metastatic bone disease is treated very differently from primary bone cancer. The treatment plan is primarily driven by the original cancer (breast, prostate, lung, kidney, etc.) — not by the bone metastasis itself. Bone-directed therapy includes (1) bone-modifying agents like zoledronic acid or denosumab to reduce fracture and skeletal events, (2) radiation therapy for painful bone metastases, (3) surgery for fractures or impending fractures, and (4) sometimes radioactive isotopes for diffuse bone metastases. CION's medical oncology and radiation oncology teams manage metastatic bone disease across all primary cancer types as part of comprehensive oncology care.

Most bone cancers are not hereditary. However, certain inherited syndromes do increase risk: Li-Fraumeni syndrome (TP53 mutations), hereditary retinoblastoma (RB1 gene), Rothmund-Thomson syndrome, and Werner syndrome. Family history of multiple cancers — particularly sarcomas, breast cancer, brain tumours in young family members — warrants genetic counselling. CION offers genetic testing and counselling where indicated.

A second opinion is especially valuable for bone cancer — both because the primary vs metastatic distinction is consequential, and because limb-sparing vs amputation decisions vary across centres. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your imaging, biopsy, and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary widely by cancer type and stage. Osteosarcoma treatment (full MAP regimen plus surgery) ranges approximately ₹8,00,000 to ₹15,00,000+ over 9–12 months. Ewing sarcoma treatment (VDC/IE plus local control) ranges similarly. Metastatic bone disease management is typically integrated with the primary cancer's treatment costs, with bone-modifying agents (zoledronic acid, denosumab) adding ₹50,000 to ₹1,00,000+ annually. Limb-sparing reconstruction with megaprosthesis adds significantly to surgical cost. For a detailed cost breakdown by treatment type, see our bone cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment begins. Aarogyasri, EMI, and cashless insurance are accepted.